Biopharmaceutical firm Juventas Cell Therapy has raked in over 400 million yuan ($62 million) in a Series C round, it said in a WeChat post on Monday.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
